CAPRI stands for the Canadian Pulmonary Radiotherapy Investigators Group. The goal of this group of Canadian radiation oncologists and medical physicists is to develop and launch cross-Canada clinical trials to answer key research questions and improve the lives of lung cancer patients. These trials seek to answer questions such as: can esophageal sparing improve quality of life for patients receiving palliative radiation for non-small cell lung cancer? (PROACTIVE n=90); in stage III non-small cell lung cancer patients receiving chemoradiation, does dose escalation to metabolically active tumor volumes improve locoregional control and overall survival? (PET-BOOST n=74), and; what is the impact of stereotactic radiation in patients with metastatic non-small cell lung cancer who have oligo-progressive disease while on systemic therapy? (STOP-NSCLC n=54).
One of CAPRI’s main initiatives is creating a national database of lung cancer imaging with QIPCM to facilitate additional retrospective research. The CAPRI group is designing trials with rapid initiation and completion, which means fewer associated costs, and the ability to implement improvements in patient care sooner.
QIPCM provided a de-identification and image transfer pipeline to each centre to anonymize all trial images before they leave each centre.
Only anonymized images are sent to QIPCM, after which they are archived in our safe, secure, and backed-up PACS. Access to these images are logged and made available only to permitted trial personnel. Permitted personnel can thus log-in to the QIPCM platform to review trial images anytime, from anywhere with internet access to meet trial deadlines.